The Population Pharmacokinetics of Imipenem in Patients With Ventilator-associated Pneumonia

This study has been completed.
Sponsor:
Collaborator:
Prince of Songkla University
Information provided by (Responsible Party):
Sutep Jaruratanasirikul, Prince of Songkla University
ClinicalTrials.gov Identifier:
NCT01489124
First received: November 23, 2011
Last updated: December 8, 2011
Last verified: December 2011
  Purpose

This is prospective, randomized and crossover design to assess the pharmacokinetic and pharmacodynamics of three regimen.

  • 0.5-hr infusion of imipenem 0.5 g every 6 hrs
  • 2-hr infusion of imipenem 0.5 g every 6 hrs
  • 2-hr infusion of imipenem 1 g every 6 hrs

Clinical and laboratory data such as Age,Sex, Body weight, CBC, Electrolyte, Vital signs, APACHE II score, BUN, Cr, Sample and Blood culture will be collected.

Nine patients will be enrolled in this study. After completion of the imipenem therapy for 3 days in this study, all patients will receive other sensitive antibiotics to eradicate their bacterial infections.

Blood samples (approximately 3 ml) will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 5 and 6 after 4th dose of imipenem.

Concentration of imipenem in plasma will be measured by HPLC method. Then, the data will be simulated in Monte Carlo technique (Computer model) to get PK/PD index (40%T>MIC) and reported to % PTA (Probability Target Attainment) and %CFR (Cumulative Faction Response).


Condition Intervention Phase
Ventilator-Associated Pneumonia
Drug: Imipenem
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Official Title: The Population Pharmacokinetics of Imipenem in Patients With Ventilator-associated Pneumonia

Resource links provided by NLM:


Further study details as provided by Prince of Songkla University:

Primary Outcome Measures:
  • Efficacy of imipenem administration by a 0.5 h and 2 h infusion [ Time Frame: At 0, 0.5, 1, 2, 3, 4, 5 and 6 hours after 4th dose of imipenem. ] [ Designated as safety issue: No ]
    Concentration of imipenem in plasma will be simulated in Monte Carlo technique (Computer model) to get PK/PD index (40%T>MIC) and reported to % PTA (Probability Target Attainment) and %CFR (Cumulative Fraction Response).


Enrollment: 9
Study Start Date: January 2008
Study Completion Date: January 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 0.5 g of imipenem by 0.5-hr infusion
0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
Drug: Imipenem
0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
Other Name: Imipenem (Tienam)
Experimental: 0.5 g of imipenem by 2-hr infusion
0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
Drug: Imipenem
0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
Other Name: Imipenem (Tienam)
Experimental: 1 g of imipenem by 2-hr infusion
1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
Drug: Imipenem
1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
Other Name: Imipenem (Tienam)

  Hide Detailed Description

Detailed Description:

Introduction: Ventilator-associated pneumonia (VAP) is a common cause of nosocomial infection with a high mortality rate. In the current era of increasing highly resistant pathogens in nosocomial infections, the empirical treatment of these organisms is becoming more difficult and only a few novel antimicrobial agents are currently in development with activity against these highly resistant Gram negative bacilli infections. Imipenem, a carbapenem antibiotic, is a β-lactam antibacterial agent with a broad spectrum of activity against both Gram positive and Gram negative bacteria. This agent is still one of the most commonly used antibiotics for empirical therapy of highly resistant nosocomial infections in VAP. In common with other β-lactams, imipenem exhibits primarily time dependent killing and increasing the concentration of this agent does not necessarily increase the rate and extent of bacterial killing. Therefore, the time that concentrations in serum are above the MIC (T>MIC) is the pharmacokinetic/pharmacodynamic (PK/PD) index that correlates with efficacy. Pharmacodynamic analysis can be applied to imipenem dosages to increase the likelihood of optimal exposure and achieve good clinical responses in patients with VAP. Previous studies we performed found that a 2 h infusion of carbapenem antibiotics gave greater values for T>MIC than a 0.5 h infusion. Therefore, in an attempt to improve the efficacy of the present β-lactam antimicrobial agents such as imipenem, a prolonged infusion would be the appropriate mode for administration to promote the maximal bactericidal effect.PK changes have been found for several hydrophilic antimicrobial agents in critically ill patients. Drug dispositions are altered in this patient population when compared with healthy subjects leading to fluctuations of plasma concentrations. Therefore, the aim of this study was to assess the PD of imipenem in VAP patients, comparing administration by 0.5 h infusion or 2 h infusion.

Objectives: To assess the pharmacokinetic and pharmacodynamics of three regimen as below.

i) 0.5-hr infusion of imipenem 0.5 g every 6 hrs ii) 2-hr infusion of imipenem 0.5 g every 6 hrs iii) 2-hr infusion of imipenem 1 g every 6 hrs

Drug preparation:Imipenem will be reconstituted with 100 ml saline solution according to the manufacturer's guidelines

Study design: This is prospective, randomized and crossover design to assess

Each patients will receive doripenem in 3 regimens consecutively:

i) 0.5-hr infusion of imipenem 0.5 g every 6 hrs ii) 2-hr infusion of imipenem 0.5 g every 6 hrs iii) 2-hr infusion of imipenem 1 g every 6 hrs

Nine patients will be enrolled in this study. After completion of the imipenem therapy for 3 days in this study, all patients will receive other sensitive antibiotics to eradicate their bacterial infections.

Sample collections: Blood samples (approximately 3 ml) will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 5 and 6 after 4th dose of imipenem. All blood samples will be allowed to clot and then centrifuged at 2,000g. The serum obtained will be stored at-80°C until analysis.

Imipenem assays by HPLC method e performed at Department of Medicine, Faculty of Medicine.

Clinical and laboratory data such as Age,Sex, Body weight, CBC, Electrolyte, Vital signs, APACHE II score, BUN, Cr, Sample and Blood culture will be collected.

Duration of study: Patients will receive imipenem for 3 days

Pharmacokinetic and pharmacodynamic analysis: Concentration of imipenem in plasma will be measured by HPLC method and simulated in Monte Carlo technique (Computer model) to get PK/PD index (40%T>MIC) and reported to % PTA (Probability Target Attainment) and %CFR (Cumulative Faction Response).

Sample Size: Nine patients with VAP will be enrolled in this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients aged ≥ 18 years
  • Patients are intubated and receiving mechanical ventilation.
  • Patients have clinical suspicion of VAP with Gram negative bacilli infections, defined by a new and persistent infiltrate on chest radiography associated with at least one of the following: purulent tracheal secretions, temperature of 38.3°C or higher or a leucocyte count higher than 10000 cells/mm3.
  • Expected life expectancy ≥ 3 days

Exclusion Criteria:

  • Patients have documented hypersensitivity to imipenem or other carbapenems.
  • Patients have an estimated creatinine clearance < 60 ml/min
  • Patients are in circulatory shock (defined as a systolic blood pressure of < 90 mmHg).
  • Patients are pregnant.
  • Pretient receive imipenem for 2 weeks before randomization.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01489124

Locations
Thailand
Prince of Songkla University
Hat Yai, Songkla, Thailand, 90110
Sponsors and Collaborators
Sutep Jaruratanasirikul
Prince of Songkla University
Investigators
Principal Investigator: Sutep Jaruratanasirikul, MD Prince of Songkha
  More Information

No publications provided

Responsible Party: Sutep Jaruratanasirikul, Principal Investigator, Prince of Songkla University
ClinicalTrials.gov Identifier: NCT01489124     History of Changes
Other Study ID Numbers: IMI-50-372-028
Study First Received: November 23, 2011
Last Updated: December 8, 2011
Health Authority: Thailand: Ethics Committee, Faculty of Medicine, Prince of Songkhla University

Keywords provided by Prince of Songkla University:
Infection
Imipenem
Ventilator-Associated Pneumonia
pharmacokinetic
pharmacodynamic

Additional relevant MeSH terms:
Pneumonia
Pneumonia, Ventilator-Associated
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Cross Infection
Infection
Ventilator-Induced Lung Injury
Lung Injury
Imipenem
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 26, 2014